Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.

Saved in:
Bibliographic Details
Title: Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.
Authors: Li R; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA., Hensley PJ; Department of Urology, University of Kentucky, Lexington, KY, USA., Babjuk M; Department of Urology, Second Faculty of Medicine, Charles University, Hospital Motol, Prague, Czech Republic., Bukavina L; Department of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA., Psutka SP; Department of Urology, University of Washington Fred Hutchinson Cancer Center, Seattle, WA, USA., Lerner SP; Department of Urology, Baylor College of Medicine, Houston, TX, USA., O'Donnell MA; Department of Urology, University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Bree KK; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Redorta JP; Department of Urology, Fundació Puigvert, Barcelona, Spain., McConkey DJ; Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Lee BH; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mariappan P; Edinburgh Bladder Cancer Surgery, The University of Edinburgh Western General Hospital, Edinburgh, UK., Mertens LS; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Soloway MS; Department of Urologic Oncology, Memorial Hospital, Hollywood, FL, USA., Svatek RS; Division of Urologic Oncology, Department of Urology, University of Texas Health Science Center, San Antonio, TX, USA., Tan WS; Department of Urology, Yale School of Medicine, New Haven, CT, USA., Williams SB; Department of Surgery, Division of Urology, University of Texas Medical Branch, Galveston, TX, USA., Gupta S; Department of Genitourinary Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Buckley R; York General Hospital, Toronto, Canada., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org.
Source: European urology oncology [Eur Urol Oncol] 2025 Dec; Vol. 8 (6), pp. 1685-1695. Date of Electronic Publication: 2025 Oct 10.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2588-9311
DOI:10.1016/j.euo.2025.08.003